## ABBV: AbbVie Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.41 indicates fundamental undervaluation. Quality metrics strong (ROE 138%). Consistent execution (4/4 quarters beat estimates). Caution: declining volume (40% of avg).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($221.39)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. 5,829 Shares in AbbVie Inc. $ABBV Bought by Regent Peak Wealth Advisors LLC**
- Source: MarketBeat | 20251227T112723 | Somewhat-Bullish | Relevance: 100%
- Regent Peak Wealth Advisors LLC purchased 5,829 shares of AbbVie Inc. (NYSE:ABBV) valued at approximately $1.35 million in the third quarter. Various other hedge funds also adjusted their positions in the company, with institutional investors and hedge funds collectively owning 70.23% of AbbVie stock. The company recently reported strong Q3 earnings, increased its quarterly dividend to $1.73 per share, and holds a "Moderate Buy" consensus rating from analysts with an average target price of $245.84.

**2. AbbVie Stock (ABBV) Before the Market Opens Dec. 26, 2025: Today’s News, Earnings Outlook, Dividend Update, and Analyst Forecasts**
- Source: ts2.tech | 20251226T001625 | Bullish | Relevance: 100%
- AbbVie Inc. (NYSE: ABBV) is entering the post-Christmas session with shares near recent highs after a strong performance in 2025. Key areas of focus for investors include the successful transition beyond Humira, driven by strong growth in Skyrizi and Rinvoq, as well as the credibility of its pipeline and its consistent dividend increases. Analysts have generally positive outlooks, with average price targets suggesting mid-to-high single-digit upside.

**3. AbbVie (ABBV) Stock on Dec. 25, 2025: After-Hours Check, Today’s Headlines, and What to Watch Before the Dec. 26 Open**
- Source: ts2.tech | 20251225T170021 | Somewhat-Bullish | Relevance: 100%
- This article provides a pre-market analysis for AbbVie (ABBV) stock on December 25, 2025, detailing its last closing price from December 24, after-hours indications, and key headlines to watch before the December 26 market open. It notes that U.S. markets were closed for Christmas Day, meaning no trading occurred, and focuses on factors like the "Santa Claus rally" effect, institutional ownership updates, and the ongoing debate about AbbVie’s fundamental valuation and pipeline success with Skyrizi and Rinvoq.

**4. Swedbank AB Buys 40,781 Shares of AbbVie Inc. $ABBV**
- Source: MarketBeat | 20251225T111738 | Bullish | Relevance: 100%
- Swedbank AB increased its stake in AbbVie Inc. (NYSE:ABBV) by 2.1% during the third quarter, purchasing an additional 40,781 shares, bringing its total holdings to 1,963,460 shares valued at approximately $454.6 million. Analyst sentiment for AbbVie is largely positive, with a consensus "Moderate Buy" rating and an average price target of $245.84. AbbVie also announced a dividend increase to $1.73 per quarter, translating to a 3.0% yield.

**5. Farther Finance Advisors LLC Has $11.04 Million Stock Position in AbbVie Inc. $ABBV**
- Source: MarketBeat | 20251225T010923 | Bullish | Relevance: 100%
- Farther Finance Advisors LLC increased its stake in AbbVie Inc. by 21.9% in Q3, now holding 47,658 shares valued at approximately $11.035 million. This increase follows AbbVie's strong Q3 performance, beating EPS and revenue expectations, and a subsequent dividend increase. Institutional investors collectively own 70.23% of AbbVie's stock.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Morgan Stanley | $269 | $261 | +3% |
| 2025-12-10 | HSBC | $265 | $225 | +18% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Morgan Stanley | main | Overweight |
| 2025-12-10 | HSBC | up | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 3 ($0.06M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.1% (+0.2%)
- Blackrock Inc.: 8.3% (-1.0%)
- JPMORGAN CHASE & CO: 6.4% (+97.6%)
- State Street Corpora: 4.5% (-0.2%)
- Morgan Stanley: 2.4% (-0.1%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_20 improving +1.0% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.41 indicates undervaluation relative to growth. Forward P/E 16.1x attractive for 34% earnings growth. Quality metrics strong (ROE 138%). Balance sheet: $6.5B free cash flow. Analyst sentiment positive (2 raises, avg +10%). Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $406.5B |
| Beta | 0.35 |
| 52W Range | $164.39 - $244.81 |
| Short Interest | 1.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.41 |
| Forward P/E | 16.1 |
| Current P/E | 21.6 |
| YoY Growth | 33.9% |
| EPS Direction | FALLING |

### Technicals

MRS_20 strengthening from -0.2% to 0.8% (+1.0% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.2pp (needs >4.0% for momentum thesis). MRS_5 at 0.2% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.58), confirming momentum. RSI neutral at 56. Volume at 40% of 20MA suggests lack of conviction. OFD pattern: +DLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.81% (CS: 63) | Neutral |
| RSI_14 | 56.1 | Neutral |
| MACD Histogram | 0.58 | Bullish |
| vs SMA20 | 1.018x | Above |
| vs SMA50 | 1.015x | Above |
| vs SMA200 | 1.118x | Above |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $230.09
- **Stop Loss:** $221.39 (3.8% risk)
- **Target:** $247.49 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 151
- **Position Value:** $34,743.59
- **Portfolio %:** 34.74%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite amid holiday trading. VIX at extreme lows (13.6) signals complacency while positive yield curve (+59bps) and stable economic data support continuation. Focus on quality names with AI/infrastructure exposure while monitoring January volatility reset.*

### Earnings

**Next:** 2026-02-06 (Est: $3.35)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.78 | $1.86 | +4.2% |
| 2025Q2 | $2.91 | $2.97 | +2.1% |
| 2025Q1 | $2.40 | $2.46 | +2.6% |
| 2024Q4 | $2.12 | $2.16 | +1.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*